BLLN BillionToOne, Inc.
USHealthcareAs of 2026-07-09 13:44
Why BLLN matters now
BillionToOne, Inc. (BLLN) is a US stock in Healthcare. The latest InvestLog snapshot shows $125.64 with +4.18% on the session and $5.78B in market capitalization; recent performance reads 1-month +27.78% and YTD +28.48%.
The latest financial table shown here is Q1 2026, with revenue of $108.4M, net income of $18.0M, and EPS of $0.34. Investors can compare that operating picture with valuation signals such as P/E 1147.45 and FCF yield 0.6%.
The latest indexable market news headline is "Tom Gardner's Five Stocks for the Long Term: Big Diversification, AI Research, and Caution" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $125.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
1147.45
PEG
10.64
P/B
9.55
P/S
13.64
EV/EBITDA
108.71
DCF Value
$929.94
FCF Yield
0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.4%
Operating Margin
10.2%
Net Margin
7.1%
ROE
7.6%
ROA
3.6%
ROIC
5.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $108.4M | $18.0M | $0.34 |
| Q4 2025 | $96.1M | $6.0M | $0.10 |
| FY 2025 | $305.1M | $7.5M | $0.06 |
| Q3 2025 | $83.5M | $1.5M | $0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$125.00
Target (Median)
$125.00
Target Range
$120.00 - $130.00
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
0.90
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.